Skip to main content
AHCO logo

AHCO · AdaptHealth Corp.

Track AHCO — free
$5.74 +0.14 (+2.50%)
Market Cap
$773.07M
Shares
136.34M
Volume · Oct 5 3.26M Avg daily vol (3M) 2.8M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.60 Open$5.73 Day$5.60–5.80 52W close$5.22–13.38 Avg vol 30d2.6M Short int9.6M · 7.1% float · 3.2d Short vol70% Last earningsAug 4, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 4 wks
filed Aug 4, 2026
call held May 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.37B
Trailing 12 months
Net income (TTM)
−$229.36M
Trailing 12 months
Revenue growth YoY
+12.7%
Year over year
Operating margin
-3.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
12.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$1.78B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.7%
Year over year · fewer shares
Price change (1Y)
-40.7%
Trailing year
Short interest
7.1%
Latest settlement · 3.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −42%
below
Price vs 50-day avg −14%
below
RSI (14) 39
neutral
MACD trend Positive
52-week position 5%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −13%
trailing
6-month return −55%
trailing
YTD return −44%
this year
Relative strength −67%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow Accumulating
1 of 241 funds reported for Sep 30 · net +1.8K sh shares
Insider flow Accumulating
Net +$275.9K over 90 days · 0% sells
Short interest Falling
7.07% of float · ▼ -7.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
241 holders — near 3-yr high, broad support
Squeeze score 50
elevated · 0–100
Fundamentals
Weak
Revenue growth −0%
Y/Y
EPS growth −185%
Y/Y
Free cash flow $219.4M
Buyback $176.8M
remaining
Balance sheet $1.6B
net debt
Quant / Vol
risk profile
Very High
Volatility 62%
annualized · 1-yr
Max drawdown −61%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Aug 4, 2026
Net revenue · fiscal year 2026 Initiated $2.85B – $2.89B
prior FY $3.24B midpoint −11.6% Y/Y
Adjusted EBITDA · fiscal year 2026 Non-GAAP Initiated $490M – $520M
Free cash flow · fiscal year 2026 Non-GAAP Initiated $80M – $120M
Guided vs delivered · last 5 settled
Net revenue fiscal year 2024
guided $3.26B – $3.32B
$3.26B In line
Net revenue fiscal year 2023
guided $3.16B – $3.19B
$3.2B Beat +0.9%
Net revenue fiscal year 2022
guided $2.95B – $3.01B
$2.97B In line
Net revenue 2021
guided $2.41B – $2.46B
$2.45B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−42% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
39 Neutral
MACD trend
Positive Bullish
52-week position
5% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $7 › 200d $10 — 200d above 50d
Institutional flow Accumulating
1 of 241 funds reported for Sep 30 · net +1.8K sh shares
Insider flow Accumulating
Net +$275.9K over 90 days · 0% sells
Short interest Falling
7.07% of float · ▼ -7.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
241 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $6 · 5% Range high $13
vs 200-day avg -42% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AHCO
AdaptHealth Corp.
this stock
$773.07M -43.8% -0.5% — 7.1%
ABT
Abbott Laboratories
$174.90B -22.2% +5.7% 28.1 1.1%
MDT
Medtronic plc
$113.38B -10.1% +8.4% 21.8 1.3%
SYK
Stryker Corp
$104.47B -21.6% +11.2% 28.2 2.0%
BSX
Boston Scientific Corp
$63.59B -55.3% +12.5% 17.8 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
241
% held
104.8%
Reported
1 of 241
Top holder
OEP CAPITAL ADVISORS, L.P.
Held Float
View
Held by Funds
Fund positions
269
View
Short & Settlement
Short Interest Falling
Shares short
9.6M
Days to cover
3.2d
Change
-759.9K sh
View
Short Volume
Short vol %
70%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$8.3K
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
39.9%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$275.9K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Congressional Trades Sell
Member
Kevin Hern
Amount
$1.0K–$15.0K
Traded
Apr 6, 2023
View
Financials
Financials
Revenue (FY)
$3.2B
Net income (FY)
$-70.8M
EPS diluted
$-0.52
View
Buybacks
Authorized
$200.0M
Remaining
$176.8M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 11, 2026
This year
16
View
Proposed Sales
Value
$117.7K
Shares
11.3K
Filed
Jul 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Sep 11, 2026
View

Performance

5D 20D 120D MTD YTD
AHCO -0.7% -12.8% -54.6% -0.7% -43.8%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -0.5% -12.3% -66.7% -1.6% -56.6%

Capital returns

Buyback program · as of Sep 30, 2023
Authorized
$200.00M
Spent (derived)
$23.20M
Remaining
$176.80M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1725255 CUSIP 00653Q102 13F (30d) 6 filings 6 filers Visit website Investor relations